Clinical trials
Recruiting Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
70 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 1 |
| 2018 | 6 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 7 |
| 2023 | 7 |
| 2024 | 15 |
| 2025 | 11 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 70 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 7 |
| Novartis Pharmaceuticals | 6 |
| Fred Hutchinson Cancer Center | 3 |
| St. Petersburg State Pavlov Medical University | 3 |
| Ascentage Pharma Group Inc. | 2 |
| Center for International Blood and Marrow Transplant Research | 2 |
| Enliven Therapeutics | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Shenzhen TargetRx Co., Ltd. | 2 |
| University Hospital, Clermont-Ferrand | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 70 |
| Leukemia, Myeloid, Acute | 28 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 23 |
| Myelodysplastic Syndromes | 22 |
| Lymphoma, Non-Hodgkin | 11 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 |
| Myeloproliferative Disorders | 10 |
| Primary Myelofibrosis | 10 |
| Hodgkin Disease | 9 |
| Leukemia, Myeloid, Chronic-Phase | 9 |
Trials
Showing 51 to 70 of 70. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.